Os Therapies Incorporated (OSTX) Stock Price, Quote & News

Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone l...

Industry: Biotechnology

Sector: Healthcare

Phone: 410 297 7793

Website: ostherapies.com

Address:

115 Pullman Crossing Road, Suite 103, Grasonville, United States

LIT_L7 May. 13 at 2:12 PM

$OSTX Making progress on all fronts. If anyone is questioning the potential, one important fact is that the FDA did waive the PDUFA fee. "Effective treatment for an untreatable patient class...", "low capitalized biotech with great product for public health", and the FDA just being nice. I made that last one up. Cheers-

0 · Reply

Gunnar1 May. 13 at 1:54 PM

$OSTX Daily chart, looks like consolidation at this range 👍

1 · Reply

biovaluable May. 13 at 1:34 PM

$OSTX the end. . .

0 · Reply

Juhanialainen May. 13 at 6:18 AM

Soon $OSTX will make a similar move like $SLS – which is my main holding. OSTX is a nice sidekick…seeing $7 this year. Better not underestimate either.

3 · Reply

biovaluable May. 13 at 3:14 AM

$OSTX OSAH IPO is fail or delay?

0 · Reply

biovaluable May. 12 at 11:12 PM

$OSTX Just a few days more accumulation time and this will go down

1 · Reply

Juhanialainen May. 12 at 7:29 PM

$OSTX Just a few days more accumulation time and this will run hard.

0 · Reply

focafoca99 May. 12 at 7:15 PM

$OSTX declares regulatory progress as EMA starts rolling review of its OST-HER2 therapy.

0 · Reply

newsfile_corp May. 12 at 6:35 PM

https://nfne.ws/297183 $OSTX @reportablenews #NYSE #Investing

1 · Reply

Joey45 May. 12 at 6:17 PM

$OSTX https://www.cnbc.com/2026/05/12/trump-fda-commissioner-marty-makary-out.html

1 · Reply

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)

Apr 30, 2026, 6:00 AM EDT - 13 days ago

OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma

Apr 27, 2026, 4:01 PM EDT - 15 days ago

OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET

Apr 16, 2026, 7:20 AM EDT - 27 days ago

OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes

Apr 13, 2026, 6:00 AM EDT - 4 weeks ago

OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor

Apr 8, 2026, 11:38 AM EDT - 5 weeks ago

OS Therapies Appoints Craig Eagle, MD as Strategic Advisor

Apr 2, 2026, 5:15 PM EDT - 5 weeks ago

OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors

2026-04-01T12:42:57.000Z - 6 weeks ago

OS Therapies price target lowered to $14 from $17 at Lake Street

Mar 31, 2026, 7:40 AM EDT - 6 weeks ago

OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update

Mar 27, 2026, 6:00 AM EDT - 6 weeks ago

OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma

Mar 25, 2026, 6:00 AM EDT - 7 weeks ago

OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma

Mar 9, 2026, 7:40 AM EDT - 2 months ago

OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting

Feb 17, 2026, 6:00 AM EST - 3 months ago

OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma

Feb 4, 2026, 12:45 PM EST - 3 months ago

OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies

Feb 2, 2026, 6:00 AM EST - 3 months ago

OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Jan 15, 2026, 7:00 AM EST - 4 months ago

OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Jan 14, 2026, 7:00 AM EST - 4 months ago

OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary

Jan 12, 2026, 8:01 AM EST - 4 months ago

OS Therapies Enters into Warrant Inducement Agreements

Jan 5, 2026, 7:40 AM EST - 4 months ago

OS Therapies Provides First Half 2026 Corporate Outlook

Dec 15, 2025, 6:00 AM EST - 5 months ago

OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Dec 11, 2025, 10:30 AM EST - 5 months ago

OS Therapies Transcript: Life Sciences Virtual Investor Forum 2025

Dec 9, 2025, 7:40 AM EST - 5 months ago

OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Dec 5, 2025, 8:01 AM EST - 5 months ago

OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility

Nov 25, 2025, 9:21 AM EST - 6 months ago

OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization

Nov 21, 2025, 4:15 PM EST - 6 months ago

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25

Nov 20, 2025, 7:40 AM EST - 6 months ago

OS Therapies to Spinoff OS Animal Health into Standalone Public Company

2025-11-18T14:39:25.000Z - 6 months ago

OS Therapies price target lowered to $17 from $18 at Lake Street

Nov 17, 2025, 6:00 AM EST - 6 months ago

OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 22, 2025, 9:15 AM EDT - 7 months ago

OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Oct 17, 2025, 9:15 AM EDT - 7 months ago

OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Oct 10, 2025, 6:00 AM EDT - 7 months ago

OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

Oct 9, 2025, 7:40 AM EDT - 7 months ago

OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting

Oct 7, 2025, 11:50 AM EDT - 7 months ago

OS Therapies to Participate in Fall 2025 Conferences and Events

Sep 30, 2025, 7:40 AM EDT - 8 months ago

OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update

Sep 19, 2025, 7:40 AM EDT - 8 months ago

OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT

Sep 12, 2025, 7:40 AM EDT - 8 months ago

OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit

Sep 8, 2025, 5:12 PM EDT - 8 months ago

Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)

Sep 3, 2025, 7:40 AM EDT - 9 months ago

OS Therapies to Participate in Upcoming Investor Conferences in September 2025

Sep 2, 2025, 7:40 AM EDT - 9 months ago

OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting

Sep 2, 2025, 6:00 AM EDT - 9 months ago

OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing

Aug 27, 2025, 4:01 PM EDT - 9 months ago

OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025

Aug 25, 2025, 9:51 PM EDT - 9 months ago

OS Therapies Terminates Equity Line of Credit

Aug 19, 2025, 6:00 AM EDT - 9 months ago

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 5:44 PM EDT - 9 months ago

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

2025-08-08T20:50:15.000Z - 9 months ago

OS Therapies files $100M mixed securities shelf

Aug 7, 2025, 9:00 AM EDT - 9 months ago

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Aug 7, 2025, 6:00 AM EDT - 9 months ago

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

2025-08-04T20:35:57.000Z - 10 months ago

OS Therapies files to sell 3.76M shares of common stock for holders

2025-07-17T19:10:39.000Z - 10 months ago

OS Therapies CEO Paul Romness sees ‘huge upside potential’

2025-07-17T19:10:33.000Z - 10 months ago

OS Therapies hopes to become commercial biotech in early 2026, CEO says

2025-07-17T19:10:27.000Z - 10 months ago

Romness sees potential FDA approval, PVR as key to OS Therapies stock

2025-07-17T19:10:21.000Z - 10 months ago

Meet OS Therapies: Fly exclusive interview with CEO Paul Romness

Jul 14, 2025, 7:40 AM EDT - 10 months ago

OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

Jul 10, 2025, 7:40 AM EDT - 10 months ago

OS Therapies Provides Clinical & Global Regulatory Updates

2025-07-03T11:55:08.000Z - 11 months ago

OS Therapies granted End of Phase 2 Meeting by FDA to review OST-HER2 program

Jul 3, 2025, 7:40 AM EDT - 11 months ago

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

2025-06-30T10:05:11.000Z - 11 months ago

OS Therapies reports ‘positive’ results from Phase 2b trial of OST-HER2

Jun 30, 2025, 6:00 AM EDT - 11 months ago

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

2025-06-24T11:56:02.000Z - 11 months ago

OS Therapies receives feedback from FDA Type D Meeting for OST-HER2 trial

Jun 24, 2025, 7:40 AM EDT - 11 months ago

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

Jun 23, 2025, 8:29 PM EDT - 11 months ago

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

2025-06-10T11:45:11.000Z - 1 year ago

OS Therapies partners with Eversana for U.S. commercialization of OST-HER2

2025-05-23T21:15:27.000Z - 1 year ago

OS Therapies files to sell 7.49M shares of common stock for holders

2025-05-16T10:05:35.000Z - 1 year ago

OS Therapies reports Q1 EPS (18c), consensus (8c)

2025-05-15T10:16:07.000Z - 1 year ago

OS Therapies forms subsidiary OS Animal Health to commercialize OST-HER2

2025-05-07T13:17:06.000Z - 1 year ago

OS Therapies announces U.S. patent for Listeria immunotherapy platform

2025-05-07T13:15:18.000Z - 1 year ago

OS Therapies Inc trading resumes

2025-05-07T12:36:46.000Z - 1 year ago

OS Therapies Inc trading halted, news pending

2025-04-22T11:55:59.000Z - 1 year ago

OS Therapies granted FDA meeting for OST-HER2

LIT_L7 May. 13 at 2:12 PM

0 · Reply

Gunnar1 May. 13 at 1:54 PM

$OSTX Daily chart, looks like consolidation at this range 👍

1 · Reply

biovaluable May. 13 at 1:34 PM

$OSTX the end. . .

0 · Reply

Juhanialainen May. 13 at 6:18 AM

Soon $OSTX will make a similar move like $SLS – which is my main holding. OSTX is a nice sidekick…seeing $7 this year. Better not underestimate either.

3 · Reply

biovaluable May. 13 at 3:14 AM

$OSTX OSAH IPO is fail or delay?

0 · Reply

biovaluable May. 12 at 11:12 PM

$OSTX Just a few days more accumulation time and this will go down

1 · Reply

Juhanialainen May. 12 at 7:29 PM

$OSTX Just a few days more accumulation time and this will run hard.

0 · Reply

focafoca99 May. 12 at 7:15 PM

$OSTX declares regulatory progress as EMA starts rolling review of its OST-HER2 therapy.

0 · Reply

newsfile_corp May. 12 at 6:35 PM

https://nfne.ws/297183 $OSTX @reportablenews #NYSE #Investing

1 · Reply

Joey45 May. 12 at 6:17 PM

$OSTX https://www.cnbc.com/2026/05/12/trump-fda-commissioner-marty-makary-out.html

1 · Reply

RunFYLife May. 12 at 6:50 AM

$OSTX

0 · Reply

Shawnflora May. 12 at 12:39 AM

$OSTX Dr. David A. Brindley at Conference call 4/30/2026: “ --- we're working on the Phase 3 design starting in Australia, for the study to be underway, the FDA's requirement is that a patient must have been recruited but not necessarily dosed. So in other words, from a cash flow perspective for the company, it's entirely possible that it starts to generate revenue from the sales of the product through conditional market authorization before there's a significant ramp-up in costs for the study itself .” ------- Minimize dilution??? 👍

0 · Reply

ZCOCSTOCK May. 11 at 10:55 PM

$OSTX man ohm man….first time today I have visited the board and this guy is ridiculous!!

1 · Reply

biovaluable May. 11 at 10:38 PM

$OSTX OSAH is fail? The end. . .

1 · Reply

edelhead May. 11 at 3:18 PM

$OSTX I continue to be super impressed by the company's almost daily posts on social media! They are incredibly transparent and confident. And there are only 7 weeks left in the second quarter, so lots of press releases coming from management between now and then.

0 · Reply

HedgeFundMgr May. 11 at 2:46 PM

$OSTX all I can say is you girls and boys are not doing a great job of spamming other boards with this jewel! lol It's 2026, and if Big Tech has taught us anything it's the value of spamming a person's feed with unwanted advertisements that you have to wait at least 5 seconds to skip - and THIS spam will likely not cost a penny but return generous reward for their time. I have always found it interesting the attitudes of people toward posters who "share" once on another board a great investment idea - be honest - how many of you have made some good dough from a "spammed" stock? It's okay for Big Tech to do it, but not the little girls and boys . . . got it! It's nearly time for the news/updates to start dropping . . . 💰💰💰

2 · Reply

God5000 May. 11 at 2:31 PM

$OSTX

2 · Reply

Wanderer2018 May. 11 at 1:20 PM

$OSTX Does anyone have the link to the recent CC webcast? Would appreciate if someone can share the link.

8 · Reply

10XCarolina May. 11 at 12:56 AM

$OSTX the beginning…

0 · Reply

biovaluable May. 10 at 11:52 PM

$OSTX the end.....

1 · Reply

Juhanialainen May. 10 at 12:40 PM

$OSTX

0 · Reply

cwork May. 9 at 5:19 PM

$OSTX “Patients with this ultra-rare type of cancer desperately need new treatment options,” said FDA Commissioner Marty Makary, M.D., M.P.H. “Through the national priority voucher pilot program, the FDA is accelerating therapies for rare diseases with unmet medical needs, reviewing applications in significantly shortened timelines. It’s like he’s talking about OS therapies 💯💯

1 · Reply

Market Cap	67.60M
Revenue (ttm)	0.00
Net Income (ttm)	-28.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	268,143
Avg Vol	658,456
Day's Range	N/A - N/A
Shares Out	39.53M
Stochastic %K	41%
Beta	-1.34
Analysts	Strong Sell
Price Target	$12.00